Sekhri, R.* et al. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies. Ann. Hematol., DOI: 10.1007/s00277-021-04647-0 (2021)
Kolb, H.J. & Schmid, C.* The FLAMSA concept-past and future. Ann. Hematol. 99, 1979–1988 (2020)
Carlet, M. ; Vergalli, J. ; Heckl, B. ; Schmidt-Supprian, M.* & Jeremias, I. MCL1 plays an essential role for patients'AML, as shown by inducible knockdown in PDX models IN VIVO. Ann. Hematol. 98, S24-S25 (2019)
Ebinger, S. ; Zeller, C. ; Spiekermann, K.* ; Vick, B. & Jeremias, I. Long-term dormancy is reversible in patients' AML cells growing in mice. Ann. Hematol. 98, S31-S32 (2019)
Liu, W.-H. ; Schwarzkopf, L. ; Herold, T. & Jeremias, I. Inducible re-expression of KLF4 impairs growth of patient derived acute lymphoma leukemia cells IN VIVO and sensitizes them towards chemotherapy. Ann. Hematol. 98, S53-S53 (2019)
Wange, L.E.* et al. Analyzing transcriptional profiles of childhood ALL at single cell resolution. Ann. Hematol. 98, S63-S64 (2019)
Wille, K.* et al. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Ann. Hematol. 98, 93-100 (2019)
Bagnoli, J.* et al. Transcriptional heterogeneity in AML - evolution of gene expression in patient derived xenografts. Ann. Hematol. 96, S59-S59 (2017)
Ebinger, S. ; Liu, W. ; Tiedt, S. ; Alves, C.C. & Jeremias, I. A rare population of drug resistant, dormant stem cells exists in patients' acute lymphoblastic leukemia growing in mice. Ann. Hematol. 96, S52-S52 (2017)
Finkenzeller, C. et al. Clones with and without sensitivity towards treatment in vivo co-exist within a single sample of a patient with ALL. Ann. Hematol. 96, S75-S75 (2017)
Heckl, B. et al. Primary adult acute lymphoblastic leukemic cells reliably engraft and grow in immunodeficient mice. Ann. Hematol. 96, S71-S72 (2017)
Koczian, F.* et al. Targeting the ER-mitochondrial interface of cell death sensitizes leukemia cells towards cytostatics. Ann. Hematol. 96, S73-S73 (2017)
Koehnke, T. et al. Early detection and alternative gating strategies in flow MRD. Ann. Hematol. 96, S26-S28 (2017)
Krupka, C. et al. Influence of cytoreductive and immunmodulatory drugs on bispecific T-cell engager-based approaches in AML. Ann. Hematol. 96, S81-S82 (2017)
Oezdemir, E. ; Ziegenhain, C.* ; Panzer-Gruenmayer, R.* ; Enard, W.* & Jeremias, I. A preclinical PDX model for patients` minimal residual disease in ALL. Ann. Hematol. 96, S74-S74 (2017)
Valtierra-Gutierrez, I.A.* et al. Detection of single-nucleotide variants in acute myeloid leukemia (AML) from bulk and single-cell RNA sequencing. Ann. Hematol. 96, S57-S57 (2017)
Vergalli, J. et al. XIAP is an attractive therapeutic target for all as validated in innovative genetically rngineered patient-derived xenograft models. Ann. Hematol. 96, S74-S75 (2017)
Vick, B. ; Holdt, L.M.* ; Hiddemann, W.R.* ; Spiekermann, K.* & Jeremias, I. Modeling AML standard induction chemotherapy in the PDX mouse model. Ann. Hematol. 96, S68-S68 (2017)
Carlet, M. ; Vergalli, J. ; Finkenzeller, C. ; Grunert, M. & Jeremias, I. Knockdown of XIAP sensitizes B-ALL cells towards chemotherapy in an innovative, dual luciferase in vivo competition assay. Ann. Hematol. 94, S88 (2015)
Carlet, M. et al. Functional characterization ofacute leukemias. Ann. Hematol. 94, S28-S30 (2015)
Ebinger, S. ; Mura, L. ; Grunert, M. & Jeremias, I. Drug sensitivity of patient-derived ALL tumor cells is impaired by co-culture with feeder cells mimicking the in vivo micro-environment. Ann. Hematol. 94, S88-S89 (2015)
Fasan, A.* et al. Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML. Ann. Hematol. 94, 1991-2001 (2015)
Finkenzeller, C. ; Carlet, M. & Jeremias, I. Single cell clones from a patient with all show different drug sensitivity and growth behavior in vivo. Ann. Hematol. 94, S89 (2015)
Greif, P.A. et al. Genetic evolution in relapsed AML. Ann. Hematol. 94, S51-S52 (2015)
Köhnke, T. et al. Flow cytometric analysis of minimal residual disease in acute myeloid leukemia. Ann. Hematol. 94, S30-S31 (2015)
Lichtenegger, F.S. et al. Next-generation dendritic cells for immunotherapy of acute myeloid leukemia. Ann. Hematol. 94, S53 (2015)
Reiter, K. et al. Visualization of AML-specific FLT3 mutants and differential downstream signaling. Ann. Hematol. 94, S82 (2015)
Tischer, J.* et al. Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: Incidence in the context of immune recovery in two different transplantation settings. Ann. Hematol. 94, 1677-1688 (2015)
Vick, B. et al. In vivo imaging facilitates reliable and sensitive monitoring of preclinical in vivo treatment trials in the individualized xenograft mouse model of AML. Ann. Hematol. 94, S83-S84 (2015)
Vosberg, S. et al. Detection of chromosome 9q deletion in Acute Myeloid Leukemia (AML) patients using targeted sequencing data. Ann. Hematol. 94, S84 (2015)
Zoellner, A.K.* et al. Temsirolimus acts as additive with bendamustine in aggressive lymphoma. Ann. Hematol. 95, 403-407 (2015)
Dufour, A.* et al. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: Independent favorable prognostic factor within NPM1 mutated patients. Ann. Hematol. 91, 1051-1063 (2012)
Eisele, L.* et al. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann. Hematol. 91, 243-248 (2012)
Hutter, G. et al. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma. Ann. Hematol. 91, 847-856 (2012)
Schneider, F.* et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann. Hematol. 91, 9-18 (2012)
Hutter, G. et al. Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation. Ann. Hematol. 88, 821-828 (2009)
Göttlicher, M. Valproic acid: An old drug newly discovered as inhibitor of histone deacetylases. Ann. Hematol. 83, 1, 91-92 (2004)
Lenz, G.* ; Hutter, G. ; Hiddemann, W. & Dreyling, M. Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia. Ann. Hematol. 83, 628-633 (2004)
Stanglmaier, M. ; Reis, S. & Hallek, M. Rituximab and Alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann. Hematol. 83, 634-645 (2004)
Pihusch, R.* et al. Platelet flow cytometric findings in patients undergoing conditioning therapy for allogeneic hematopoitic stem cell transplantation. Ann. Hematol. 81, 454-461 (2002)
Nüßler, V. et al. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes - First experience with their reversal. Ann. Hematol. 69, S25-S29 (1994)
Hoffmann-Fezer, G. et al. Biotin Labeling as an Alternative Non-Radioactive Approach for Determination of Red Cell Survival. Ann. Hematol. 67, 81-87 (1993)
Hoffmann-Fezer, G. et al. Biotin labeling as an alternative nonradioactive approach to determination of red cell survival. Ann. Hematol. 67, 81-87 (1993)
Busch, F.W. et al. Myelopoiesis in Vitro is Suppressed by Hepatitis A Virus. Ann. Hematol. 64, 1, A132-A136 (1992)
Reininger, C.B. et al. Increased Platelet Activity in Postsurgical Patients. Ann. Hematol. 64 (Suppl.), S. A6 (1992)
Hahn, J. et al. Positive Selection of Canine Hemopoietic Progenitor Cells. Ann. Hematol. 14, 59-60 (1991)
Hahn, J. et al. Immunological characterization of canine hematopoietic progenitor cells. Ann. Hematol. 63, 223-226 (1991)
Hoffmann-Fezer, G. et al. Direct in vivo biotinylation of erythrocytes as an assay for red cell survival studies. Ann. Hematol. 63, 214-217 (1991)